Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5% [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the safety and efficacy of Lotemax Ophthalmic Suspension 0.5% has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Conjunctivitis
• Giant Papillary Conjunctivitis
• Seasonal Allergic Conjunctivitis

Drugs mentioned

• Lotemax Ophthalmic Suspension 0.5% (loteprednol etabonate)

Snippet

Sponsor: Bausch & Lomb Incorporated | Conditions: Conjunctivitis, Seasonal Allergic, Conjunctivitis, Giant Papillary | Phase 4 | Status: COMPLETED